Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Amgen logo
AmgenAMGN
$571M+14.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.79M+9.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$3M-200%
Erasca, Inc. logo
Erasca, Inc.ERAS
$1.18M-34.1%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$3.67M+206%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s change in AP?
IDEAYA Biosciences, Inc. (IDYA) reported change in AP of $3.05M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s change in AP changed year-over-year?
IDEAYA Biosciences, Inc.'s change in AP increased by 11.8% year-over-year, from $2.73M to $3.05M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.